Cosmo Pharmaceuticals S.p.A. is a specialty pharmaceutical company based in Lainate, Italy, that focuses on developing and manufacturing products for gastrointestinal diseases, dermatology, and health technologies. The company's proprietary pipeline includes treatments for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, as well as products for colon infections. Notable offerings include Lialda/Mezavant, aimed at managing ulcerative colitis, and Aemcolo, which addresses travellers' diarrhoea. Cosmo is also advancing several products in clinical trials, such as Budesonide MMX for ulcerative colitis remission, Rifamycin SV MMX for travellers' diarrhoea, and an injectable LMW Heparin MMX for anticoagulation. Additionally, the company is exploring treatments for dermatological conditions like acne through products like Winlevi. Cosmo Pharmaceuticals also manufactures products for third parties, expanding its global reach in the pharmaceutical market.
Cristoforo Colombo Real Estate is a provider of real estate services.
BioXell
Acquisition in 2009
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.